The standard therapy for patients with haemophilia is prophylactic treatment with
replacement factor VIII (FVIII) or factor IX (FIX). Patients who develop inhibitors against …

The revised UKHCDO factor (F) VIII/IX Inhibitor Guidelines (2000) are presented. A schema
is proposed for inhibitor surveillance, which varies according to the severity of the …

Abstract The International Immune Tolerance Study was a multicenter, prospective,
randomized comparison of high-dose (HD; 200 IU/kg/d) and low-dose (LD; 50 IU/kg 3 …

1School of Medicine, Cardiff University, University Hospital of Wales, Wales, 2Royal
Hospital for Sick Children, Glasgow, 3The London School of Medicine and Dentistry, Royal …

Factor IX (FIX) inhibitors develop in 1· 5–3% of haemophilia B patients. Due to its low
incidence compared with that in haemophilia A, few comparable data exist on host and …

Although immune tolerance induction (ITI) has been used for 30 years to eliminate inhibitors
and restore normal factor pharmacokinetics in patients with hemophilia, there is a paucity of …

The North American Immune Tolerance Registry was initiated to study of immune tolerance
(ITT) in Canada and the United States with respect to: 1) therapeutic regimens in use for …

Introduction The formation of neutralizing antifactor VIII (fVIII) antibodies, called inhibitors, is
the most common complication in modern haemophilia A care. Novel non‐factor …

The most significant complication of treatment in patients with hemophilia A is the
development of alloantibodies that inhibit factor VIII activity. In the presence of inhibitory …

In oncology, an increasing number of targeted anticancer agents and immunotherapies are
of biological origin. These biological drugs may trigger immune responses that lead to the …